Indications for Suspecting Non‑Diabetic Kidney Disease (NDKD) in Diabetic Patients

Clinical Predictors that Prompt Kidney Biopsy

• In diabetic patients, the presence of atypical features—absence of diabetic retinopathy, diabetes duration < 2 years, rapid decline in kidney function, active urinary sediment, or nephrotic‑range proteinuria without retinopathy—should trigger consideration of NDKD and a kidney biopsy. 1

• Absence of diabetic retinopathy has a negative predictive value of 81 % and a positive predictive value of 88 % for NDKD, making it a strong discriminator. 1

• Rapidly declining eGFR or a sudden increase in proteinuria, especially when reaching nephrotic range, markedly raises the likelihood of NDKD. 1

• Active urinary sediment (dysmorphic red blood cells, red‑cell casts) is highly suggestive of a glomerular process other than diabetic nephropathy. 1

• Clinical evidence of systemic disease (e.g., vasculitis, lupus) that could cause glomerulonephritis warrants biopsy to differentiate NDKD from diabetic kidney disease. 1

• When the underlying etiology remains uncertain or when a specific therapy would change management, a kidney biopsy is recommended. 1

Safety Profile of Kidney Biopsy

• The overall complication rate of percutaneous kidney biopsy in CKD patients is comparable to that in other renal diseases; it is not increased solely by the presence of CKD. 1

• Bleeding risk after biopsy is higher in females, younger individuals, those with lower eGFR, uncontrolled hypertension, and when more than four needle passes are performed. 1

• Failure to obtain a timely biopsy in diabetic patients with atypical features leads to misdiagnosis in > 50 % of cases, underscoring the need for early tissue diagnosis. 1

Diagnostic Evaluation and Confirmation of Chronic Kidney Disease

Initial Laboratory Assessment

• Simultaneous measurement of estimated GFR (eGFR) using serum creatinine and spot urine albumin‑to‑creatinine ratio (ACR) is required for all patients at risk of CKD. 2

• Adding cystatin C to creatinine‑based equations (eGFRcr‑cys) provides the most accurate GFR estimate when available. 2

• Urinalysis with microscopy should be performed to detect active sediment (e.g., dysmorphic RBCs, casts). 3

Confirmation of Chronicity

• Abnormal eGFR or ACR values must be repeated after at least 3 months to distinguish chronic kidney disease from acute kidney injury or transient proteinuria. 2

• Chronicity can also be established by reviewing prior laboratory trends, renal ultrasound findings of reduced kidney size or cortical thinning, or biopsy evidence of fibrosis/atrophy. 2

Imaging

• Renal ultrasound is the first‑line imaging modality to evaluate kidney size, cortical thickness, and to exclude obstruction; small kidneys with cortical thinning support a chronic process. 2

Three‑Dimensional CKD Classification

• CKD should be classified simultaneously by cause, GFR category (G1‑G5), and albuminuria category (A1‑A3). This framework integrates etiologic, functional, and proteinuric information. 4

• GFR categories are defined as:

  • G1 ≥ 90 mL/min/1.73 m², G2 = 60‑89, G3a = 45‑59, G3b = 30‑44, G4 = 15‑29, G5 < 15 mL/min/1.73 m² or dialysis. 3

• Albuminuria categories are: A1 < 30 mg/g, A2 30‑300 mg/g, A3 > 300 mg/g.

Cardiovascular Risk Management in CKD

• Adults ≥ 50 years with eGFR < 60 mL/min/1.73 m² (stages G3a‑G5) should receive a statin or a statin/ezetimibe combination. 4

• Adults ≥ 50 years with eGFR ≥ 60 mL/min/1.73 m² (stages G1‑G2) should receive statin monotherapy. 4

• For adults 18‑49 years with CKD, initiate statin therapy if any of the following are present: known coronary disease, diabetes, prior ischemic stroke, or a 10‑year cardiovascular risk > 10 %. 4

• Low‑dose aspirin is recommended for secondary prevention in patients with established ischemic cardiovascular disease. 4

Monitoring Frequency and Nephrology Referral

Stage‑Specific Monitoring

*Monitoring schedule derived from KDIGO‑endorsed recommendations. 5

Nephrology Referral Criteria

• Immediate referral is indicated for eGFR < 30 mL/min/1.73 m² (stages G4‑G5). 5

• Referral is also warranted for ACR ≥ 300 mg/g, rapid eGFR decline (> 5 mL/min/1.73 m² per year), or when the etiology of kidney disease is uncertain (e.g., heavy proteinuria, active sediment, absent retinopathy in diabetics, rapid decline). 5

• Consider earlier referral (eGFR 45‑60 mL/min/1.73 m²) if non‑diabetic disease is suspected, resistant hypertension, or abnormal renal ultrasound findings. 5

Management of Mineral‑Bone Disorder and Bone Health

• Assess vitamin D status and ensure sufficiency; monitor PTH, calcium, and phosphorus at intervals appropriate to CKD stage. 5

• Bone mineral density testing is recommended when eGFR is between 45‑60 mL/min/1.73 m². 5

Additional Clinical Pearls

• Do not attribute a single abnormal eGFR or ACR to CKD without confirming chronicity, as acute kidney injury or transient proteinuria can mimic CKD. 2

• Do not discontinue RAAS blockade solely because of modest creatinine rises (< 30 %); these changes are hemodynamic and the long‑term renal benefits outweigh the transient effect.

• In patients with refractory hypertension or a marked eGFR drop after initiating RAAS blockade, evaluate for renal artery stenosis. 1

Evaluation of Chronic Kidney Disease

Initial Detection and Confirmation

• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend testing all at-risk patients, such as those with diabetes, hypertension, cardiovascular disease, or family history of kidney failure, using both serum creatinine for eGFR calculation and spot urine albumin-to-creatinine ratio (ACR) 6
• The American College of Physicians suggests using creatinine-based eGFR (eGFRcr) as the initial assessment; if cystatin C is available, combine both markers (eGFRcr-cys) for more accurate GFR estimation in adults at risk 6
• Confirming chronicity by repeating abnormal tests after 3 months is necessary to distinguish CKD from acute kidney injury or acute kidney disease 6
• Proof of chronicity can also be established through review of past measurements, imaging showing reduced kidney size or cortical thinning, kidney biopsy findings of fibrosis, or medical history of conditions causing CKD 6

Three-Dimensional Classification System

• The KDIGO 2024 guidelines mandate classifying CKD using all three dimensions simultaneously: cause, GFR category, and albuminuria category 7, 6
• Establish etiology through clinical context, personal and family history, social and environmental factors, medications, physical examination, laboratory measures, imaging, and when indicated, genetic testing or kidney biopsy 6
• The National Kidney Foundation defines GFR categories as follows: G1: eGFR ≥90 mL/min/1.73 m², G2: eGFR 60-89 mL/min/1.73 m², G3a: eGFR 45-59 mL/min/1.73 m², G4: eGFR 15-29 mL/min/1.73 m², G5: eGFR <15 mL/min/1.73 m² 8, 9, 10
• The American Heart Association defines albuminuria categories as follows: A1: ACR <30 mg/g, A2: ACR 30-300 mg/g, A3: ACR >300 mg/g 11, 10, 7

Risk Stratification and Prognosis

• The KDIGO guidelines recommend using externally validated risk equations to estimate absolute risk of kidney failure in patients with CKD G3-G5 7
• A 5-year kidney failure risk of 3-5% triggers nephrology referral consideration; 2-year risk >10% indicates need for multidisciplinary care; 2-year risk >40% mandates preparation for kidney replacement therapy 7
• For cardiovascular risk prediction, use externally validated models developed within CKD populations or that incorporate both eGFR and albuminuria 7

Comprehensive Laboratory Evaluation

• Assess the following beyond eGFR and ACR: complete metabolic panel, complete blood count, lipid panel, hemoglobin A1c, parathyroid hormone (PTH) and 25-hydroxyvitamin D, and iron studies 7, 11, 9

Monitoring Schedule

• Monitor eGFR and ACR annually for CKD G1-G2, every 6 months for CKD G3a, every 3 months for CKD G3b-G4, and monthly or as clinically indicated for CKD G5 11, 7

Imaging and Additional Testing

• Renal ultrasound is recommended to assess kidney size, cortical thickness, and rule out obstruction or structural abnormalities 6
• Kidney biopsy is considered when diagnosis is uncertain, when specific treatment would change management, or when rapid progression occurs without clear cause 6

Nephrology Referral Criteria

• Immediate referral is mandatory when eGFR <30 mL/min/1.73 m², ACR ≥300 mg/g, or rapid decline in eGFR 8, 9, 11

Critical Management Principles During Evaluation

• Avoid nephrotoxins such as NSAIDs, aminoglycosides, contrast agents, and proton pump inhibitors when possible 8
• Adjust medication dosing based on eGFR for renally cleared drugs 8
• Evaluate iron status before treating anemia 11

Common Pitfalls to Avoid

• Do not assume single abnormal eGFR or ACR represents CKD—acute kidney injury or transient proteinuria can cause temporary abnormalities 6
• Do not delay treatment initiation while waiting to confirm chronicity if CKD is highly likely based on clinical context 6
• Do not use age-adjusted definitions of CKD—reduced eGFR and albuminuria carry prognostic significance at all ages 9, 6